ナノ粒子のサイズと表面化学は,血清タンパク質の吸収とマクロファージの吸収を決定する
Carl D Walkey1, Jonathan B Olsen, Hongbo Guo
1Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada M5S 3G9.
Journal of the American Chemical Society
|December 24, 2011
まとめ
ナノ粒子の性質が体内でどのように変化するかを理解することは,ナノ医療の鍵です. この研究は,金ナノ粒子のサイズと表面化学がタンパク質吸収に影響し,マクロファージがそれらと相互作用する方法を影響することを示しています.
科学分野:
- バイオメディカルエンジニアリング
- ナノテクノロジー ナノテクノロジー
- 材料科学 材料科学とは
背景:
- 配達と毒性は,ナノ医療における重要な課題である.
- ナノマテリアルの物理化学的特性と,in vivoの相互作用の関係性は,十分に理解されていません.
- ナノマテリアルの"生物的同一性"は,生理学的変化による"合成的同一性"と異なる.
研究 の 目的:
- 金ナノ粒子 (AuNP) のサイズと表面化学が血清タンパク質吸収にどのように影響するか調査する.
- タンパク質吸収がマクロファージでAuNPの吸収に与える影響を決定する.
- 臨床的に有用なナノマテリアルを設計するための原則を確立する.
主な方法:
- ラベルなしの液体染色学タンデム質量スペクトロメトリー (LC-MS/MS) を利用して,吸収された血清タンパク質を特定および定量化しました.
- 合成された金ナノ粒子は,サイズとポリエチレングリコール (PEG) 接ぎ木密度が異なる.
- ナノ粒子の吸収を評価するために,マクロファージの細胞系との共培養されたAuNP.
主要な成果:
- 70以上の血清タンパク質が,AuNPの表面に異質的に吸収されていることが確認されました.
- 吸収されたタンパク質の組成と密度は,AuNPのサイズとPEGの移植密度によって変化した.
- タンパク質吸収プロフィールの差異は,マクロファージの吸収のメカニズムと効率の変化と相関しています.
結論:
- ナノ粒子のサイズと表面化学は,タンパク質コロナの決定的な決定因子です.
- タンパク質のコロナは,ナノ粒子-細胞の相互作用,特にマクロファージの吸収に大きな影響を与えます.
- タンパク質吸収を考慮したナノマテリアルの合理的な設計は,in vivoの投与を改善し,毒性を減らすために不可欠です.
さらに関連する動画
関連する概念動画
Factors Affecting Protein-Drug Binding: Protein-Related Factors
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
Factors Affecting Protein-Drug Binding: Drug-Related Factors
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In contrast,...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In contrast,...
Drug Binding to Blood Components
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...


